FDAClass IIFebruary 2, 2022

Pioglitazone Tablets USP recall: Superpotent

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Why was Pioglitazone Tablets USP recalled?

Superpotent and Failed Tablet/Capsule Specifications

What should I do if I have this product?

Review the official FDA enforcement record for current instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Batch # PF4520028B & PF4520028A, Exp. Date 11/2022

Product
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
Recalling firm
Aurobindo Pharma USA Inc.
Quantity
792 bottles
Distribution
Nationwide in the US
Recall date
February 2, 2022
Classification
Class II
Status
Terminated
Agency
FDA (drug)
Open FDA enforcement record Latest recalls